Abstract:
The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
Abstract:
An alloy composition includes from about 4 wt % to about 11 wt % of silicon based on a total wt % of the alloy composition; from about 0.1 wt % to about 0.5 wt % of chromium based on the total wt % of the alloy composition; from about 0.1 wt % to about 0.5 wt % of magnesium based on the total wt % of the alloy composition; from about 0.01 wt % to about 0.05 wt % of titanium based on the total wt % of the alloy composition; equal to or less than 0.5 wt % of iron based on the total wt % of the alloy composition; equal to or less than 0.5 wt % of manganese based on the total wt % of the alloy composition; and a balance of aluminum.
Abstract:
The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A′, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Abstract:
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Abstract:
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Abstract:
A detection apparatus comprises a freely-movable integral framework provided with front wheels and rear wheels, characterized in that, a control portion and a scan portion, and a driving mechanism driving said framework to move are provided on said framework, wherein said framework is provided with a first interface for connecting to external power, so that said detection apparatus is driven by external power via the driving mechanism to perform detection while conducting detection on site, and wherein the semitrailer for mounting the framework is provided with a second interface connectable to a traction apparatus so as to connect the detection apparatus and the traction apparatus while carrying out site-changing transportation. Said detection apparatus is not affected by the alteration of the emission standards, has low failure rate and maintenance cost, has zero emission in the detection state, and is pollution-free.
Abstract:
The present invention discloses a method of designing a set of two tiled masks, as well as, a mask including: a first tile, the first tile being transparent to a light, the first tile having a first characteristic linear dimension that is 15% or less of a wavelength of the light; a second tile, the second tile being transparent to the light, the second tile having a second characteristic linear dimension that is 15% or less of the wavelength of the light; and a third tile, the third tile being opaque to the light, the third tile having a third characteristic linear dimension that is 15% or less of the wavelength of the light.
Abstract:
Described herein is mask design and modeling for a set of masks to be successively imaged to print a composite pattern on a substrate, such as a semiconductor wafer. Further described herein is a method of double patterning a substrate with the set of masks. Also described herein is a method of correcting a drawn pattern of one of the mask levels based on a predicted pattern contour of the other of the mask levels. Also described herein is a method of modeling a resist profile contour for a mask level in which photoresist is applied onto a inhomogeneous substrate, as well as method of predicting a resist profile of a Boolean operation of two masks.
Abstract:
An electronic device support includes a V-shaped base, a supporting leg, a cable and a number of lights. The V-shaped base includes a pair of legs extending from an apex of the V-shaped base. The supporting leg is pivotably connected to the V-shaped base adjacent to the apex. The cable is embedded in at least one of the legs and the supporting leg and includes a connector plug electrically connected to the other end. The lights are rotatably mounted on one of the distal end of the legs of the base away from the apex of the V-shaped base.